Concepedia

The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.

Josée Golay, Elena Cittera, Nicola Di Gaetano, Massimiliano Manganini, Michela Mosca, Manuela Nebuloni, Nico van Rooijen, Luca Vago, Martino Introna

PubMed · 2006 · 130 citations · 35 references

Abstract

These data demonstrate that complement is required for the therapeutic activity of rituximab in vivo in a murine model of B-cell lymphoma, independently of its localization in lymph nodes or subcutaneously.

References

35

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations

, , +5

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity

Robert L. Shields, Jadine Lai, Rodney G. Keck et al. · Journal of Biological Chemistry · 2002 · 1.8K citations · Full text

, , +23

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

Pierre Feugier, Ambro van Hoof, Catherine Sebban et al. · Journal of Clinical Oncology · 2005 · 1.5K citations

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Wen‐Kai Weng, Ronald Levy · Journal of Clinical Oncology · 2003 · 1.3K citations